Class of Recommendation and Level of Evidence S1.5-1. Halperin JL, Levine GN, Al-Khatib SM, et al. Further evolution of the ACC/ AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2015;133:1426 8. 2. HIGH BLOOD CHOLESTEROL AND ASCVD 2.1. Serum Cholesterol, Lipoproteins, and ASCVD 2.1.2. Cholesterol, LDL-C, and ASCVD S2.1.2-1. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT) JAMA. 1986;256:2823 8. S2.1.2-2. Kannel WB, Castelli WP, Gordon T, et al. Serum cholesterol, lipopro- teins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med. 1971;74:1 12. S2.1.2 3. Lawes CMMVH, S, Law MR, Rogers A. High Cholesterol. Ezzati M, Lopez AD, Rodgers A, et al Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors. 2004. Geneva, Switzerland: World Health Organization, 391 496. Available at: http://apps.who.int/iris/ handle/10665/42770. S2.1.2-4. Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of ath- erogenic lipoproteins and the risk for cardiovascular events: a meta- analysis of statin trials. J Am Coll Cardiol. 2014;64:485 94. S2.1.2-5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387 97. S2.1.2-6. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clini- cal outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713 22. S2.1.2-7. Silverman MG, Ference BA, Im K, et al. Association between lower- ing LDL-C and cardiovascular risk reduction among different thera- peutic interventions: a systematic review and meta-analysis. JAMA. 2016;316:1289 97. 2.1.3. 